Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ: SUPN · Real-Time Price · USD

44.63

-0.98 (-2.15%)

At close: Jul 31, 2026, 4:00 PM EDT

45.01

+0.38 (0.85%)

After-hours: Jul 31, 2026, 7:45 PM EDT

Supernus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	184.87	128.45	69.33	75.05	93.12	203.43
Short-Term Investments	199.37	180.22	384.28	179.82	368.21	136.25
Cash & Short-Term Investments	384.24	308.67	453.61	254.87	461.33	339.68
Cash Growth	-17.12%	-31.95%	77.98%	-44.75%	35.81%	-19.61%
Accounts Receivable	182.18	187.8	142.08	144.16	165.5	148.93
Inventory	87.06	82.39	54.29	77.41	91.54	85.96
Other Current Assets	78.09	65.33	36.09	16.68	15.78	27.02
Total Current Assets	731.58	644.18	686.07	493.11	734.15	601.59
Net Property, Plant & Equipment	10.04	10.53	11.55	13.53	15.17	16.96
Other Intangible Assets	549.71	569.46	521.91	599.89	702.46	784.69
Goodwill	120.67	124.88	117.02	117.02	117.02	117.52
Long-Term Investments	-	-	-	16.62	93.9	119.17
Other Long-Term Assets	88.72	103.6	31.53	37.51	39.81	49.23
Total Assets	1,501	1,453	1,368	1,278	1,703	1,689

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	101.24	107.8	76.35	79.57	96.34	117.68
Accrued Expenses	189.72	161.1	168.71	154.27	151.67	132.72
Short-Term Debt	-	-	-	-	401.97	-
Other Current Liabilities	82.97	69.27	47.34	56.35	37.98	64.97
Total Current Liabilities	373.93	338.17	292.4	290.2	687.96	315.38
Long-Term Debt	-	-	-	-	-	379.25
Long-Term Leases	30.27	30.37	27.38	33.2	36	41.3
Other Long-Term Liabilities	19.72	22.4	12.56	32.77	92.35	137.37
Total Long-Term Liabilities	49.99	52.76	39.94	65.96	128.35	557.92
Total Liabilities	423.92	390.93	332.34	356.16	816.3	873.3

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.06	0.06	0.06	0.06	0.05	0
Additional Paid-in Capital	561.42	543.83	479.44	439.49	408.12	434.34
Accumulated Other Comprehensive Income	-0.26	-0.04	-0.19	-0.59	-3.21	1.54
Retained Earnings	515.58	517.88	556.43	482.56	481.25	379.92
Shareholders' Equity	1,077	1,062	1,036	921.52	886.2	815.85
Total Liabilities & Equity	1,501	1,453	1,368	1,278	1,703	1,689

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	30.27	30.37	27.38	33.2	437.97	420.55
Net Cash (Debt)	353.97	278.31	426.23	221.68	23.37	-80.87
Net Cash Growth	-19.04%	-34.71%	92.27%	848.64%	-	-
Net Cash Per Share	6.21	4.93	7.62	3.99	0.38	-1.49
Book Value	1,077	1,062	1,036	921.52	886.2	815.85
Book Value Per Share	18.88	18.81	18.51	16.60	14.37	15.01
Tangible Book Value	406.43	367.38	396.8	204.61	66.72	-86.36
Tangible Book Value Per Share	7.12	6.51	7.09	3.69	1.08	-1.59

SEC Filings: 10-K · 10-Q